Meditope Biosciences is a biotechnology company developing best-in-class antibody-based cancer products. Discovered at City of Hope, Meditope's technology is capable of turning any monoclonal antibody (mAb) into a proprietary, site-specific "Lego-like" system that is able to attach and detach drugs to antibodies without the need for chemical conjugation. The result is a memAb (meditope-enabled mAb) product that is significantly more effective and offers multiple manufacturing advantages compared to existing antibody-drug conjugate technologies.
Novel Monoclonal Antibody Linker Technology Platform
Best-in-class antibody-based cancer products
PARTNERING WITH MEDITOPE
We are focused on advancing our monoclonal antibody technology platform through a differentiated partnering approach designed to create more efficacious and better-tolerated antibody-drug conjugates.
NEWS & EVENTS
July 26, 2013
Meet us at World ADC Summit, San Francisco
October 25, 2013
Co-Founder John Williams presenting at Antibody & Protein Tx Conference